Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608874 | 0.82 | PIK3C3 (0.40) | PIK3C3HTR5AUSP30 | |
| SCHEMBL20216282 | 0.79 | KCNH2 (0.54) | KCNH2USP30NOS3NOS1NOS2 | |
| SCHEMBL17233037 | 0.74 | USP30 (0.44) | KCNH2USP30 | |
| SCHEMBL20177129 | 0.74 | PIK3C3 (0.44) | KCNH2PIK3C3 | |
| SCHEMBL17233437 | 0.73 | PIK3C3 (0.39) | KCNH2PIK3C3NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL8807386 | 0.72 | MAPT (0.47) | PIK3C3HTR5AKDM4EMEN1KMT2A | |
| SCHEMBL3173446 | 0.72 | GAA (0.60) | KDM4EMEN1KMT2AROCK2ROCK1 | |
| SCHEMBL18609161 | 0.72 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL22574230 | 0.71 | PIK3C3 (0.42) | PIK3C3HTR5AKDM4EMEN1KMT2A | |
| SCHEMBL20215529 | 0.70 | KCNH2 (0.68) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PARMACEUTICAL CO. LTD (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | SPIN1, SULT1A1, NAP1L1 | KCNH2 1420/4885PIK3C3 1337/4885HTR5A 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.